Post My Press Release

Free Press Release Distribution

Category: Pharmaceutical Industry (Page 1 of 44)

Inhalation Anesthesia Market New Opportunities For Industry Growth And Forecast To 2025 : Grand View Research Inc.

San Francisco, 24 May 2019: The Report Inhalation Anesthesia Market Size Share & Trends Analysis Report By Application (Induction, Maintenance), By Product (Sevoflurane, Isoflurane, Desflurane), By Region, And Segment Forecasts, 2019 – 2025

The global Inhalation Anesthesia Market size is projected to reach USD 1.42 billion by 2015, at a lucrative CAGR of 3.5% over the forecast period, according to a new report by Grand View Research, Inc. Key factors contributing to its rapid growth include increasing prevalence of cancer, cardiovascular, respiratory, neurological, gastrointestinal, orthopedic, and spinal diseases and disorders.

Furthermore, increasing number of emergency cases and demand for short stay ambulatory day care surgical procedure are amongst critical success factors attributed to the market growth. Access to universal health insurance coverage for a wider population base coupled with constant improvements in healthcare infrastructure in various developing countries are expected to positively impact the number of surgeries performed, thus increasing the usage of inhalation anesthetics.

On the basis of product, the inhalation anesthesia market is classified into sevoflurane, isoflurane, and desflurane. These products are used for induction and maintenance of anesthesia for patients during surgical procedures. Sevoflurane led the product segment in 2018 and is anticipated to grow at a lucrative rate over the forecast period, attributed to its therapeutic advantages, low cost, and higher potency for the induction of anesthesia. On the other hand, isoflurane is expected to witness the fastest CAGR of 6.3% over the forecast period, due to its increasing use in maintenance of anesthesia for treatment of weak or geriatric patients owing to its sparing effect on cardiovascular function.

On the basis of regions, the market is broadly classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa (MEA). North America held the leading market share of USD 456.0 million and is anticipated to witness lucrative CAGR over the forecast period. This is owing to increasing prevalence of chronic diseases coupled with the presence of advanced healthcare facilities. On the other hand, Asia Pacific was anticipated to witness the fastest CAGR of 4.0% due to increasing population and number of patients suffering from chronic population.

Some of the key players operating in this market include Halocarbon Products Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.

Access Research Report of Inhalation Anesthesia Market @ www.grandviewresearch.com/industry-analysis/inhalation-anesthesia-market

Further key findings from the report suggest:

  • Sevoflurane product segment led the market in terms of revenue, valued at USD 768.6 million, in 2018
  • Isoflurane product segment is anticipated to expand at the fastest CAGR of 6.3% owing to its increasing use in the treatment of weak and geriatric patients owing to its low effect on cardiovascular function
  • North America led the market in 2018 with a revenue of USD 456.0 million owing to the presence of advanced healthcare facilities, strong reimbursement scenario, and prevalence of chronic diseases
  • Key players operating in the inhalation anesthesia market include Halocarbon Products Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global inhalation anesthesia market on the basis of product and region:

Inhalation Anesthesia Product Type Outlook (Revenue, USD Million, 2014 – 2025)

  • Sevoflurane
  • Isoflurane
  • Desflurane

Inhalation Anesthesia Application Type Outlook (Revenue, USD Million, 2014 – 2025)

  • Induction
  • Maintenance

Inhalation Anesthesia Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • NorthAmerica
  • Europe
  • AsiaPacific
  • Latin America
  • MEA

Access Press Release of Inhalation Anesthesia Market @ www.grandviewresearch.com/press-release/global-Inhalation-Anesthesia-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Antifungal Drugs Market Share, Growth Analysis And Industry Size Forecasts To 2025 : Grand View Research Inc.

San Francisco, 7 June 2019: The Report Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis), and Segment Forecasts, 2018 – 2025

The global antifungal drugs market size is expected to reach USD 12.7 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 1.5% during the forecast period. Increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, rise in adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in increased incidence of fungal infections in recent years.

According to statistics published by the Centers of Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to high prevalence of mycological infections around the globe.

As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, rise in geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2025 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Access Research Report of Antifungal Drugs  Market @ www.grandviewresearch.com/industry-analysis/antifungal-drugs-market

Further key findings from the study suggest:

  • Several types of fungicidal preparations, such as creams, sprays, tablets, & injections, are available. Increasing adoption of these products is anticipated to drive the market during the forecast period
  • The echinocandins segment is anticipated to exhibit lucrative growth owing to their cell wall-specific fungicidal property coupled with their broad-spectrum activity against Aspergillusand Candida species without cross-resistance risks
  • The candidiasis indication segment is expected to witness the fastest CAGR over the forecast period due to increasing drug resistance of the Candida species to Azoles
  • North America held the largest market share in 2017. The growth of the market can be attributed to higher awareness levels pertaining to treatment of fungal infection and presence of a large target population
  • Asia pacific is projected to register the fastest growth during the forecast period due to improving healthcare facilities coupled with rising government initiatives to create awareness of infectious diseases among the population
  • Companies are focusing on development of effective therapeutic agents for treatment of systemic fungal infections in immune-compromised patients
  • Numerous ongoing public-private partnership agreements in the pharmaceutical industry for development of novel therapeutics is poised to provide the market with lucrative growth opportunities. For instance, Astellas Pharma partnered with Vical Incorporated for the development of VL-2397, an antifungal drug for the treatment of pulmonary aspergillus.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global antifungal drugs market by drug class, indication, and region:

Antifungal Drug Class Outlook (Revenue, USD Million, 2014 – 2025)

  • Azoles
    • Voriconazole (Vfend)
    • Posaconazole (Noxafil)
    • Clotrimazole (Canesten)
    • Isavuconazole (CRESEMBA)
    • Others
  • Echinocandins
    • Caspofungin (Cancidas)
    • Micafungin (Mycamine/ Funguard)
    • Others
  • Polyenes
    • Amphotericin (AmBisome)
    • Others
  • Allylamines
    • Terbinafine (Lamisil)
    • Others
  • Others

Antifungal Drugs Indication Outlook (Revenue, USD Million, 2014 – 2025)

  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
    • Invasive Candidiasis
    • Vulvovaginal Candidiasis (VVC)
    • Mouth/Throat/Esophageal Candidiasis
    • Other Candida Infections
  • Others

Antifungal Drugs Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Access Press Release of Antifungal Drugs  Market @ www.grandviewresearch.com/press-release/global-antifungal-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Contrast Injectors Market

Global Contrast Injectors Market – Industry Trends and Forecast to 2021

According to a new market research report ” Contrast Injectors Market by Product (Injector Systems (CT Injector, MRI Injector), Consumables (Injector Head, Tubing), Accessories), & Application (Radiology, Interventional Cardiology, Interventional Radiology) – Global Forecast to 2021″, published by MarketsandMarkets™, this report studies the global market for the forecast period of 2016 to 2021. This market is expected to reach USD 636.1 Million by 2021 from USD 445.5 Million in 2016, growing at a CAGR of 7.4%.

On the basis of product, the contrast injector market is categorized into injector systems, consumables, and accessories. In 2016, the consumables segment is estimated to account for the largest share of the contrast injector market. This growth is mainly attributed to the recurring use of consumables in diagnostic procedures to maintain hygienic conditions. The injector systems segment is further divided into CT injector systems, MRI injector systems, and angiography injector systems. In 2016, the CT injector systems segment is expected to command the largest share of the market.

The MRI injector systems segment is expected to grow at the highest CAGR during the forecast period. The consumables segment is further divided into injector heads, syringes, tubing, and other consumables (scan bags, valves, vials, and spikes). In 2016, the injector heads segment is estimated to account for the largest share of the consumables market. The injector heads segment is further categorized into single head injectors, dual head injectors, and syringeless injectors. 

The single head injectors segment is expected to command the largest share of the market, in 2016. The syringeless injectors segment is projected to grow at the highest CAGR during the forecast period. On the basis of application, the contrast media injector market is segmented into radiology, interventional cardiology, and interventional radiology. In 2016, the radiology segment is estimated to command the largest share of the contrast injector market. The interventional cardiology segment is expected to grow at the highest CAGR during the forecast period.

Key players in the global contrast injector market include Bracco Imaging S.p.A. (Italy), Bayer HealthCare (Germany), Guerbet Group (France), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), GE Healthcare (U.S.), AngioDynamics (U.S.), Nemoto Kyorindo Co., Ltd. (Japan), Sino Medical- Device Technology Co., Ltd. (China), VIVID IMAGING (China), and Apollo RT Co., Ltd. (China).

Know more about the Medical Connectors Market: https://www.marketsandmarkets.com/PressReleases/contrast-injector.asp

Ophthalmic Drugs Market Overall Growth, Future Scope, Industry Trends And Forecast 2026 : Grand View Research Inc.

San Francisco, 27 June 2019: The Report Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Disease (Retinal Disorder, Allergies), By Dosage Form (Eye Drops, Eye Solutions), By Product Type, And Segment Forecasts, 2019 – 2026

The global ophthalmic drugs market size is expected to reach USD 43.1 billion by 2026 registering a CAGR of 4.5%, according to a new report by Grand View Research, Inc. Increased funding by public and private bodies for conducting research on ocular disorders and presence of strong emerging pipeline drugs are some of the factors responsible for the growth of ophthalmic therapeutics market. For instance, Shire and Parion Sciences collaborated to develop and commercialize P-321, which will be used in the treatment of dry eye diseases in adults. In addition, approval of novel products for the treatment of eye disorders is expected to propel the market.

For instance, in 2017, Nicox, received FDA approval of ZERVIATE (cetirizine ophthalmic solution) for treating ocular itching associated with allergic conjunctivitis. This product is the first topical ocular formulation of antihistamine.Key companies, such as Novartis AG, Bausch & Lomb Inc., and Pfizer, Inc., are involved in mergers & acquisitions to increase their market share. In 2017, Johnson & Johnson Services, Inc acquired Abbott Medical Optics, Inc. With this acquisition, all the products of Abbott Medical Optics, Inc. including consumer eye health, laser refractive surgery, and cataract surgery portfolio will be sold under the name of Johnson & Johnson.

Access Research Report of Ophthalmic Drugs Market @  www.grandviewresearch.com/industry-analysis/ophthalmic-therapeutics-drug-market

Further key findings from the study suggest:

  • Anti-VEGF agent led the market in 2018 and is anticipated to register the fastest CAGR of 7.9% from 2019 to 2026 owing to its wide usage in treating eye disorders, such as age-related macular degeneration and diabetic retinopathy
  • Retinal disorder was estimated to be the largest segment and is considered to be the fastest-growing disease segment over the forecast period due to increasing prevalence of diabetic retinopathy
  • Eye drops led the market in 2018 and is projected witness the highest CAGR due its cost-effectiveness as compared to other dosage forms
  • Prescription drugs held the largest share in 2018 since it is considered to be more effective treatment
  • OTC type is said to be the fastest-growing segment over the forecast period owing to easy accessibility of OTC drugs
  • North America led the market in 2018 due to increasing demand for ophthalmic products for the treatment of dry eye and glaucoma
  • Asia Pacific is anticipated to be the fastest growing regional market during the forecast period due to awareness programs conducted by various organizations and rising disposable income levels
  • Some of the key companies in this market are Novartis AG; Bausch & Lomb, Inc.; Regeneron Pharmaceuticals, Inc.; Allergan PLC; Pfizer, Inc.; Bayer AG; Santen Pharmaceutical Co., Ltd.; and Genentech, Inc.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global ophthalmic drugs market on the basis of drug class, disease, dosage form, product type, and region:

Ophthalmic Drugs Drug Class Outlook (Revenue, USD Million, 2014 – 2026)

  • Antiallergy
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Agents
  • Anti-inflammatory
    • Nonsteroidal Drugs
    • Steroidal Drugs
  • Antiglaucoma
  • Others

Ophthalmic Drugs Disease Outlook (Revenue, USD Million, 2014 – 2026)

  • Dry Eye
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye Drops
    • Ointments
  • Allergies
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Glaucoma
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Inflammation/Infection
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Retinal Disorders
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Uveitis
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Others

Ophthalmic Drugs Dosage Form Outlook (Revenue, USD Million, 2014 – 2026)

  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments

Ophthalmic Drugs Product Type Outlook (Revenue, USD Million, 2014 – 2026)

  • Prescription Drugs
  • OTC Drugs

Ophthalmic Drugs Regional Outlook (Revenue, USD Million, 2014 – 2026)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Access Press Release of Ophthalmic Drugs Market @ www.grandviewresearch.com/press-release/global-ophthalmic-therapeutics-drug-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Antibody Drug Conjugates Market Projected To Grow Moderately At CAGR 25.9% Through 2025 : Grand View Research Inc.

San Francisco, 10 July 2019: The Report Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Brain Tumor, Blood, Breast, Ovarian, Lung Cancer), By Technology (Cleavable, Non-cleavable Linker), And Segment Forecasts, 2019 – 2025

The global antibody drug conjugate market size is expected to reach USD 9.93 billion by 2025, according to a new report by Grand View Research, Inc. it is projected to expand at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore, major technological advancements are also contributing to drive the growth. According to the World Health Organization (WHO), the number of people aged 65 years and above, is projected to reach 16% of the total population by 2050 from 7% in 2000. Aging has become a substantial risk factor for numerous diseases including cancer and others. Hence, the growing geriatric population is expected to drive growth of the market over the forecast period.

Until 2018, four ADCs were available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate targeting and improved technology, ADCs have been gaining a lot of attention from both small and large pharmaceutical companies. Currently there are more than 50 ADCs in clinical trials and it has been projected that during the forecast period three to four ADCs will be commercialized in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma.

Seattle Genetics and Roche are leading the antibody drug conjugate market in terms of market share. Until 2017 only two ADCs were commercially available-Adcetris by Seattle Genetics and Kadcyla by Roche. Recently, two more Pfizer’s products were approved to be marketed for acute myeloid leukaemia and acute lymphoblastic leukaemia. Hence, it has been estimated that over the forecast period, Pfizer is anticipated to gain a significant market share.

Access Research Report of Antibody Drug Conjugates Market @ www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market

Further key findings from the report suggest:

  • Breast cancer was the largest segment in 2017 and is likely to witness a significant growth over the forecast period due to the factors such as availability of Kadcyla and high prevalence of breast cancer
  • Cleavable linker is expected to witness the fastest growth over the forecast period as the maximum product in the pipeline contains cleavable linkers. In addition, in 2017 two new products-Besponsa and Mylotarg were approved in the market
  • In 2017, North America was the largest revenue generating region in the antibody-drug conjugates market. It is the most well-established regions in terms of patient awareness and usage of ADCs and makes up most of the existing market
  • The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
  • Market players are adopting strategies, such as introducing technologically advanced products, collaborations, and geographic expansions to increase their market share. For instance, Seattle Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global antibody drug conjugate market on the basis of application, technology, and region:

Antibody Drug Conjugate Application Outlook (Revenue, USD Million, 2014 – 2025)

  • Blood Cancer
    • Leukemia
    • Lymphoma
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor

Antibody Drug Conjugate Technology Outlook (Revenue, USD Million, 2014 – 2025)

  • Cleavable Linker
  • Non-cleavable Linker

Antibody Drug Conjugate Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Access Press Release of Antibody Drug Conjugates Market @ www.grandviewresearch.com/press-release/global-antibody-drug-conjugates-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

High Potency Active Pharmaceutical Ingredients (APIs) Market Detailed Analysis For Industry Size, Share And Future Assumptions For 2025 : Grand View Research Inc.

San Francisco, 24 May 2019: The Report High Potency Active Pharmaceutical Ingredients (APIs) Market Analysis By Product (Synthetic, Biotech), Manufacturer (In-house, Outsourced), Drug Type, Therapeutic Application (Oncology, Hormonal, Glaucoma, Others), And Segment Forecasts, 2018 – 2025

The global High Potency Active Pharmaceutical Ingredients (APIs) Market is expected to reach USD 34.8 billion by 2025, according to a new report by Grand View Research, Inc. Increasing number of new entrants producing fast relief therapeutics in emerging countries of India and China is anticipated to boost the demand for High potency active pharmaceutical ingredients (HPAPIs) over the forecast period. 

In addition, supportive government regulations for commercialization and research and development of novel drug molecules are projected to drive the industry growth. Extensive capital investments required for development of production facility has lead to increase in contract manufacturing activities for HPAPIs during the forecast period.

Access Research Report of High Potency Active Pharmaceutical Ingredients (APIs) Market @ www.grandviewresearch.com/industry-analysis/high-potency-active-pharmaceutical-ingredients-hpapi-market

Further Key Findings From the Study Suggest:

  • Synthetic route of High PotencyAPIs dominated the overall market in terms of revenue share as of 2016 owing to presence of large manufacturers producing these type of molecules
  • Biotech HPAPI segment is expected to be the fastest growing and is expected to grow at a lucrative growth ratedue torising demand for cancer drugs and fueling research and developmentactivities pertaining to it
  • Innovative drug market dominated the overall drug type in 2016. Generic drug segment is expected to be the fastest growing segment. The factors attributing to its growth are patent expiration of various drugs and increasing demand for the cancer treatment
  • Contact outsourcing segment is anticipated to show lucrative growth as major pharmaceuticals are focused on rigorous research and development activities for new drug development
  • Oncology segment heldlargest revenue share as of 2016, due to increasing demand for anti-cancerous drugs
  • North America HPAPIs market held the largest market share as of 2016. Growing prevalence of chronic disease patients, and established research and development infrastructure for novel drug development are factors supporting to major share of this market
  • Patent expiration of major drugs in North American and European countries is anticipated to fuel market growth
  • Asia Pacific regional market is expected to register significant growth owing to growing investments in biotechnology sector and rapidly growing oncology market
  • The key players in the HPAPI market includeBristol-Myers Squibb,  Sigma-Aldrich Corporation, Pfizer Incand Lonza among others
  • Extensive research and development activities carried out by market participants is also expected to augment the market growth

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the High PotencyAPIsmarket on the basis of the product, manufactures, drug types, application, and region:

HPAPIs Product Outlook (Revenue, USD Million, 2014 – 2025)

  • Synthetic
  • Biotech

HPAPIs Manufacturers Outlook (Revenue, USD Million, 2014 – 2025)

  • In-house
  • Outsourced

HPAPIs Drug Types Outlook (Revenue, USD Million, 2014 – 2025)

  • Innovative
  • Generic

HPAPIs Application Outlook (Revenue, USD Million, 2014 – 2025)

  • Oncology
  • Hormonal
  • Glaucoma
  • Others

HPAPIs Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Access Press Release of High Potency Active Pharmaceutical Ingredients (APIs) Market @ www.grandviewresearch.com/press-release/global-high-potency-active-pharmaceutical-ingredients-hpapi-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

EMEA 3D CBCT Market

4 Major EMEA 3D CBCT/Cone Beam CT Systems Market Drivers to Watch – MarketsandMarkets

According to a new market research report “EMEA 3D CBCT Marketby Application (Dental (Oral and Maxillofacial Surgery, Implantology, Orthodontic, Endodontic) and Non-Dental (Radiology, ENT)), End User (Hospitals and Clinics, Diagnostic Centres) – Forecast to 2023″, published by MarketsandMarkets™, the market is expected to reach USD 300.4 Million by 2023 from an estimated USD 194.3 Million in 2018, at a CAGR of 9.0%.

Browse 74 market data Tables and 17 Figures spread through 115 Pages and in-depth TOC on “EMEA 3D CBCT/Cone Beam CT Systems Market”

Ask for Expert Advice – https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=148086734

Early buyers will receive 10% customization on this report 

With increasing disposable incomes, rising healthcare expenditure, and the availability of health insurance, the willingness to undergo expensive cosmetic procedures in various countries has increased. Moreover, the rising expenditure on treatments for appearance enhancements is driving the demand for dental products in the market.

By application, the dental segment accounted for the largest share of the EMEA 3D CBCT Systems Market in 2017 

On the basis of application, the market is broadly segmented into dental and non-dental applications. The dental applications segment further sub segmented into implantology, oral and maxillofacial surgery, orthodontics, endodontics, and other dental applications. The non-dental applications segment is sub segmented into ENT and radiology. The dental application segment accounted for the largest share of EMEA 3D CBCT Systems Market in 2017. Large geriatric population in the European countries, technological enhancements, wide adoption of 3D CBCT systems in dental implant procedures, and the growing focus on the evaluation of post-treatment cases are factors attributed to the large share of dental application.

By type, ENT segment accounted for the largest share of the non-dental application market in 2017 

Based on the type, the non-dental application market is further segmented into ENT and radiology. In 2017, ENT segment accounted for the largest share of this market. This dominant share is attributed to the increasing use of CBT imaging in the diagnosis of ENT disorders due to advantages such as high spatial resolution, better visibility of small details, lower radiation exposure compared to traditional CT, patient convenience during examination, and compatibility of CBCT systems with surgical navigation/image-guided surgery systems during ear surgeries.

Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=148086734

Europe dominated the market in 2017 

Europe accounted for the largest share of the EMEA 3D CBCT Systems Market in 2017, followed by the Middle East and Africa. The largest share of the European region is mainly attributed to the rising geriatric population, increasing awareness about oral healthcare, rising incidence of dental diseases, growing demand for advanced cosmetic dental procedures, growing dental tourism in some European countries, and the increasing number of dental clinics and hospitals in the region.

The key players in the EMEA 3D CBCT Systems Market are Danaher Corporation (US), DENTSPLY SIRONA (US), Carestream Dental (US), Planmeca Group (Finland), VATECH (South Korea), CEFLA (Italy), J. MORITA CORPORATION (Japan), ACTEON GROUP (France), Asahi Roentgen (Japan), and Genoray (South Korea).

Know more about the EMEA 3D CBCT/Cone Beam CT Systems Market: https://www.marketsandmarkets.com/PressReleases/emea-3d-cbct.asp

Global Pharmacy Automation Systems Market Latest Study, Research & Growth in near future 2023

Pharmacy automation involves the mechanical processes of handling and distributing medications. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Pharmacy Automation Systems Report by Material, and Geography – Global Forecast to 2023 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

In this report, the global Pharmacy Automation Systems market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2023, growing at a CAGR of XX% during the period 2019 to 2023.

Download Free Sample Report @ https://www.radiantinsights.com/research/global-pharmacy-automation-systems-market-research-report-2019-2023/request-sample

Pharmacy Automation Systems Market
Pharmacy Automation Systems Market

The report firstly introduced the Pharmacy Automation Systems basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include:

• Baxter
• BD
• McKesson
• Swisslog

The end users/applications and product categories analysis:

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

• Plastics
• Metal
• Paper

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Pharmacy Automation Systems for each application, including-

• Automated Medication Dispensing Systems
• Automated Storage & Retrieval Systems
• Automated Packaging & Labeling Systems

Browse Full Research Report with TOC @ https://www.radiantinsights.com/research/global-pharmacy-automation-systems-market-research-report-2019-2023

Table of Contents

Part I Pharmacy Automation Systems Industry Overview

Chapter One Pharmacy Automation Systems Industry Overview
1.1 Pharmacy Automation Systems Definition
1.2 Pharmacy Automation Systems Classification Analysis
1.2.1 Pharmacy Automation Systems Main Classification Analysis
1.2.2 Pharmacy Automation Systems Main Classification Share Analysis
1.3 Pharmacy Automation Systems Application Analysis
1.3.1 Pharmacy Automation Systems Main Application Analysis
1.3.2 Pharmacy Automation Systems Main Application Share Analysis
1.4 Pharmacy Automation Systems Industry Chain Structure Analysis
1.5 Pharmacy Automation Systems Industry Development Overview
1.5.1 Pharmacy Automation Systems Product History Development Overview
1.5.1 Pharmacy Automation Systems Product Market Development Overview
1.6 Pharmacy Automation Systems Global Market Comparison Analysis
1.6.1 Pharmacy Automation Systems Global Import Market Analysis
1.6.2 Pharmacy Automation Systems Global Export Market Analysis
1.6.3 Pharmacy Automation Systems Global Main Region Market Analysis
1.6.4 Pharmacy Automation Systems Global Market Comparison Analysis
1.6.5 Pharmacy Automation Systems Global Market Development Trend Analysis

Chapter Two Pharmacy Automation Systems Up and Down Stream Industry Analysis
2.1 Upstream Raw Materials Analysis
2.1.1 Proportion of Manufacturing Cost
2.1.2 Manufacturing Cost Structure of Pharmacy Automation Systems Analysis
2.2 Down Stream Market Analysis
2.2.1 Down Stream Market Analysis
2.2.2 Down Stream Demand Analysis
2.2.3 Down Stream Market Trend Analysis

Part II Asia Pharmacy Automation Systems Industry (The Report Company Including the Below Listed But Not All)

Chapter Three Asia Pharmacy Automation Systems Market Analysis
3.1 Asia Pharmacy Automation Systems Product Development History
3.2 Asia Pharmacy Automation Systems Competitive Landscape Analysis
3.3 Asia Pharmacy Automation Systems Market Development Trend

Chapter Four 2014-2019 Asia Pharmacy Automation Systems Productions Supply Sales Demand Market Status and Forecast
4.1 2014-2019 Pharmacy Automation Systems Production Overview
4.2 2014-2019 Pharmacy Automation Systems Production Market Share Analysis
4.3 2014-2019 Pharmacy Automation Systems Demand Overview
4.4 2014-2019 Pharmacy Automation Systems Supply Demand and Shortage
4.5 2014-2019 Pharmacy Automation Systems Import Export Consumption
4.6 2014-2019 Pharmacy Automation Systems Cost Price Production Value Gross Margin
.
.
.
.
Part VI Global Pharmacy Automation Systems Industry Conclusions

Chapter Eighteen 2014-2019 Global Pharmacy Automation Systems Productions Supply Sales Demand Market Status and Forecast
18.1 2014-2019 Pharmacy Automation Systems Production Overview
18.2 2014-2019 Pharmacy Automation Systems Production Market Share Analysis
18.3 2014-2019 Pharmacy Automation Systems Demand Overview
18.4 2014-2019 Pharmacy Automation Systems Supply Demand and Shortage
18.5 2014-2019 Pharmacy Automation Systems Import Export Consumption
18.6 2014-2019 Pharmacy Automation Systems Cost Price Production Value Gross Margin

Chapter Nineteen Global Pharmacy Automation Systems Industry Development Trend
19.1 2019-2023 Pharmacy Automation Systems Production Overview
19.2 2019-2023 Pharmacy Automation Systems Production Market Share Analysis
19.3 2019-2023 Pharmacy Automation Systems Demand Overview
19.4 2019-2023 Pharmacy Automation Systems Supply Demand and Shortage
19.5 2019-2023 Pharmacy Automation Systems Import Export Consumption
19.6 2019-2023 Pharmacy Automation Systems Cost Price Production Value Gross Margin

Chapter Twenty Global Pharmacy Automation Systems Industry Research Conclusions

Read all Reports of this category @ https://www.radiantinsights.com/catalog/pharmaceutical

About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assists and facilitate organizations and individuals procure market research reports, helping them in the decisions making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:
Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Phone: (415) 349-0054
Toll Free: 1-888-928-9744
Address: 201 Spear Street 1100, Suite 3036,
City: San Francisco; State: California; Country: United States
Email: sales@radiantinsights.com
Website: https://www.radiantinsights.com/

Page 1 of 44

Powered by WordPress & Theme by Anders Norén